

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

1. (Currently Amended) A vaccine composition comprising pharmaceutically acceptable particles selected from polymeric microcapsules or liposomes, the particles comprising a biologically active agent that generates a protective immune response in an animal to which it is administered; in combination with an adjuvant chemical which increases the effect of the biologically active agent by acting as an immunostimulant, said adjuvant chemical being selected from the group consisting of:

- A) polyornithine,
- B) a member selected from the group consisting of water soluble vitamins ~~or~~ and water soluble vitamin derivatives,
- C) a member selected from the group consisting of positively charged cationic block copolymers and ~~or~~ a positively charged cationic surfactants,
- D) a clathrate,
- E) a complexing agent,
- F) cetrimides,
- G) a S-layer protein,
- H) Methyl-glucamine;

subject to the following provisos

a) when the adjuvant chemical is selected from A, the composition is for administration to a mucosal surface, ~~or~~ and

b) ~~when the adjuvant chemical is selected from C, the composition does not contain polyacrylic acid~~ when the particles are polymeric microcapsules, they are either obtainable

using a double emulsion solvent evaporation method or have an adjuvant chemical incorporated at the surface.

Claims 2-3. (Cancelled)

4. (Previously Presented) The composition of claim 1 wherein the adjuvant chemical is selected from one or more of:

- A) polyornithine having a molecular weight from 5 to 150 kDa,
- B) vitamin E TPGS (d-alpha tocophenyl polyethylene glycol 1000 succinate),
- C) a cationic block copolymer or a cationic surfactant, positively charged by means of  $\text{NH}_2^+$  groups,
- D) a complexing agent that forms complexes with fatty acids, or
- E) cyclodextrin or a derivative thereof.

5. (Cancelled)

6. (Previously Presented) The composition of claim 1 wherein the particles are liposomes.

7. (Currently Amended) The composition of claim 1 wherein the particles are ~~microcapsule~~ microcapsules.

8. (Currently Amended) The composition of claim 7 wherein the ~~microspheres~~ microcapsules are prepared using a high molecular weight polymer.

9. (Previously Presented) The composition according to claim 8 wherein the polymer has a molecular weight of 100 kDa or more.

10. (Currently Amended) The composition according to ~~any one of~~ claims 7 ~~to 9~~ wherein the ~~microsphere comprises~~ microcapsules comprise poly-(L-lactide).

11. (Cancelled)

12. (Previously Presented) The composition of claim 1 which is administered to a mucosal surface of an animal or administered parenterally to the animal. *NFL*

13. (Currently Amended) The composition of claim ~~2~~ 1 which further comprises a second adjuvant.

Claims 14-25. (Cancelled)

Claims 26-28. (Withdrawn)

29. (Previously Presented) The composition of Claim 1 wherein the adjuvant chemical is a cationic block copolymer or a cationic surfactant, positively charged by means of  $\text{NH}_2^+$  groups.

Claims 30-32. (Withdrawn)

33. (New) The composition of claim 7 wherein the adjuvant chemical is coated on the surface of the microcapsule. *UK*